The Dermatophytosis drugs in development market research report provides comprehensive information on the therapeutics under development for Dermatophytosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dermatophytosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dermatophytosis and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Dermatophytosis by eight companies/universities/institutes. The top development phase for Dermatophytosis is phase ii with five drugs in that stage. The Dermatophytosis pipeline has nine drugs in development by companies and one by universities/ institutes. Some of the companies in the Dermatophytosis pipeline products market are: Vyome Therapeutics, DermBiont and Taro Pharmaceuticals USA.
The key targets in the Dermatophytosis pipeline products market include Lanosterol 14 Alpha Demethylase, and Squalene Monooxygenase.
The key mechanisms of action in the Dermatophytosis pipeline product include Lanosterol 14 Alpha Demethylase Inhibitor with three drugs in Phase II. The Dermatophytosis pipeline products include three routes of administration with the top ROA being Topical and two key molecule types in the Dermatophytosis pipeline products market including Small Molecule, and Biologic.
Dermatophytosis overview
Dermatophytosis, also known as ringworm, is a fungal infection of the skin. Typically it results in a red, itchy, scaly, circular rash. Hair loss may occur in the area affected. Symptoms begin four to 14 days after exposure. It is caused by areas of hair, skin, or nails being infected by a dermatophyte, which is most commonly of the Trichophyton genus and less commonly of the Microsporum or Epidermophyton genera. Tinea capitis, tinea pedis, and onychomycosis are common dermatologic diseases that may result from such an infection.
For a complete picture of Dermatophytosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
